Marshall Wace LLP Purchases 167,476 Shares of AtriCure, Inc. (NASDAQ:ATRC)

Marshall Wace LLP increased its holdings in shares of AtriCure, Inc. (NASDAQ:ATRC - Free Report) by 37.1% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 619,166 shares of the medical device company's stock after acquiring an additional 167,476 shares during the period. Marshall Wace LLP owned approximately 1.27% of AtriCure worth $18,922,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in ATRC. Heck Capital Advisors LLC purchased a new position in shares of AtriCure during the 4th quarter worth approximately $60,000. Venturi Wealth Management LLC raised its holdings in shares of AtriCure by 1,337.6% in the fourth quarter. Venturi Wealth Management LLC now owns 2,257 shares of the medical device company's stock valued at $69,000 after buying an additional 2,100 shares during the last quarter. KBC Group NV grew its position in AtriCure by 65.3% in the 4th quarter. KBC Group NV now owns 2,360 shares of the medical device company's stock valued at $72,000 after buying an additional 932 shares during the last quarter. R Squared Ltd purchased a new stake in shares of AtriCure in the fourth quarter valued at approximately $89,000. Finally, AlphaQuest LLC increased its holdings in AtriCure by 855.1% in the fourth quarter. AlphaQuest LLC now owns 5,062 shares of the medical device company's stock valued at $155,000 after buying an additional 4,532 shares in the last quarter. Hedge funds and other institutional investors own 99.11% of the company's stock.

Wall Street Analyst Weigh In

ATRC has been the topic of several recent analyst reports. Stifel Nicolaus upped their price objective on shares of AtriCure from $36.00 to $48.00 and gave the company a "buy" rating in a research note on Thursday, February 13th. Piper Sandler increased their price target on shares of AtriCure from $40.00 to $50.00 and gave the stock an "overweight" rating in a research report on Thursday, February 13th. JMP Securities restated a "market outperform" rating and set a $60.00 price objective on shares of AtriCure in a research note on Monday, February 10th. Canaccord Genuity Group lowered their price objective on shares of AtriCure from $66.00 to $52.00 and set a "buy" rating on the stock in a research note on Friday, March 28th. Finally, Needham & Company LLC reaffirmed a "buy" rating and set a $51.00 target price on shares of AtriCure in a research report on Thursday, March 27th. One analyst has rated the stock with a hold rating and nine have issued a buy rating to the company's stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $49.44.

AtriCure Price Performance

Shares of ATRC traded down $0.49 during trading hours on Friday, hitting $33.26. 158,439 shares of the company were exchanged, compared to its average volume of 652,215. AtriCure, Inc. has a fifty-two week low of $18.94 and a fifty-two week high of $43.11. The company has a quick ratio of 2.62, a current ratio of 3.65 and a debt-to-equity ratio of 0.13. The firm's fifty day moving average is $34.42 and its 200 day moving average is $34.51. The company has a market cap of $1.63 billion, a price-to-earnings ratio of -34.99 and a beta of 1.65.

Insider Activity

In related news, Director Karen Prange sold 6,100 shares of the stock in a transaction on Wednesday, March 5th. The stock was sold at an average price of $38.12, for a total value of $232,532.00. Following the completion of the sale, the director now directly owns 17,828 shares of the company's stock, valued at approximately $679,603.36. This represents a 25.49 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders own 3.20% of the company's stock.

About AtriCure

AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.